Skip to main content
Premium Trial:

Request an Annual Quote

Morningstar Gives Illumina a BB+ Credit Rating

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment research firm Morningstar has initiated a credit rating for Illumina of BB+, which it said reflects its negative view of the genetic analysis instrument business.

Morningstar said that although Illumina's financial position "looks solid," its rating "recognizes the fundamental advantages of competing in this industry." It also used Affymetrix's "recent downfall" in market position as a cautionary note for Illumina's creditors.

"While Illumina currently is dominating its target niches, particularly in sequencing, we believe it is very difficult to sustain competitive advantages in this market for the long run," said Morningstar. "Users of genetic analysis tools gravitate toward the best throughput … and easiest to use options. If new entrants or existing competitors eventually surpass Illumina in those characteristics, demand for Illumina's tools could decline or profit-damaging pricing pressure could ensue in this business."

It also said that Illumina's currently solid financial position — which includes an estimated $748 million in cash and short-term investments versus $390 million in outstanding principal on its convertible debt issue maturing in February 2014 — could take a hit if the firm is forced to spend big on an acquisition.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.